{"id":5707,"date":"2016-08-19T14:29:25","date_gmt":"2016-08-19T12:29:25","guid":{"rendered":"https:\/\/www.institut-biotherapies.fr\/en\/?page_id=5707"},"modified":"2016-08-19T14:29:25","modified_gmt":"2016-08-19T12:29:25","slug":"facioscapulohumeral-dystrophy","status":"publish","type":"page","link":"https:\/\/www.institut-biotherapies.fr\/en\/muscle-diseases\/facioscapulohumeral-dystrophy\/","title":{"rendered":"Facioscapulohumeral Dystrophy"},"content":{"rendered":"<p>Facioscapulohumeral Dystrophy (FSHD), also called Landouzy-Dejerine, is due to a modification of structure on a small region\u00a0of chromosome 4, the D4Z4 region. It occurs with a muscular weakness affecting muscles of the face, shoulders, and arms, usually during adolescence or adulthood.<\/p>\n<p>&nbsp;<\/p>\n<h2>ATYR-C4 study<\/h2>\n<ul>\n<li><strong>Reference laboratory:\u00a0<\/strong>Institute of Myology<\/li>\n<\/ul>\n<p>This open-label, intrapatient dose escalation study aims at\u00a0evaluating the safety, tolerability, immunogenicity, and biological activity of ATYR1940 in patients with limb girdle and facioscapulohumeral muscular dystrophies.<\/p>\n<p>For further information: <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02579239\" target=\"_blank\">ATYR-C4 study webpage<\/a><\/p>\n<h2>ATYR-C3 study<\/h2>\n<ul>\n<li><strong>Reference laboratory:\u00a0<\/strong>Institute of Myology<\/li>\n<\/ul>\n<p>This open-label, intrapatient dose-escalation study aims at evaluating the safety, tolerability, immunogenicity, and biological activity of ATYR1940 in patients with early onset and other pediatric onset facioscapulohumeral muscular dystrophy.<\/p>\n<p>For further information: <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02603562\" target=\"_blank\">ATYR-C3 study webpage<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Facioscapulohumeral Dystrophy (FSHD), also called Landouzy-Dejerine, is due to a modification of structure on a small region\u00a0of chromosome 4, the D4Z4 region. It occurs with a muscular weakness affecting muscles of the face, shoulders, and arms, usually during adolescence or adulthood. &nbsp; ATYR-C4 study Reference laboratory:\u00a0Institute of Myology This open-label, intrapatient dose escalation study aims &hellip; <a href=\"https:\/\/www.institut-biotherapies.fr\/en\/muscle-diseases\/facioscapulohumeral-dystrophy\/\">[Read more]<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"parent":4283,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-5707","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/pages\/5707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/comments?post=5707"}],"version-history":[{"count":1,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/pages\/5707\/revisions"}],"predecessor-version":[{"id":5708,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/pages\/5707\/revisions\/5708"}],"up":[{"embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/pages\/4283"}],"wp:attachment":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/media?parent=5707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}